Dian Diagnostics Group Co.,Ltd. (DIAN DIAGNOSTICS GROUP CO LTD) Aktie

Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. In addition, the company offers supply chain optimization, information management, cold chain logistics, intelligent warehousing, sample library management, scientific research services, etc., as well as solutions for laboratory quality. Further, it is involved in the research and development of diagnostic products; and vitro diagnostic reagents, as well as forensic identification, health management, and other fields. The company was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. and changed its name to Dian Diagnostics Group Co.,Ltd. in November 2017. Dian Diagnostics Group Co.,Ltd. was founded in 1996 and is based in Hangzhou, China.